Dr. Risch graduated from the University of California San Diego School of Medicine with a medical degree and the University of Chicago School of Medicine with a doctorate in mathematical epidemic modelling.
Dr. Risch worked as a postdoctoral researcher in epidemiology at the University of Washington before joining the faculty at the University of Toronto, where he taught epidemiology and biostatistics.
Cancer causation, prevention, and early detection are Dr. Risch’s primary research interests. He is particularly interested in the influence of cancer aetiology on reproductive variables.
food, genetic predisposition, histopathologic factors, occupational/environmental/medication exposures, infection and immunological functioning.
The cure for Covid-19 was found by Yale epidemiology professor Dr. Harvey Risch.Hydroxychloroquine treatment for COVID-19 patients drew the attention of the professor. In addition to this, he is reported to have explored a variety of other unconventional subjects.
Rebound cases in COVID patients on Paxlovid were discussed by him on the show recently with Fox News.Oncology research initiatives have included studies of ovarian and pancreatic cancer.
as well as those relating to the use of oral contraception and non-contraceptive estrogens in the treatment of breast and prostate cancer.
It has been six years since Dr. Risch was a member of the American Journal of Epidemiology’s Board of Editors, but he is still an Associate Editorial Board Member and Editor of the journal’s International Journal of Cancer.
In the medical literature, Dr. Risch has published more than 400 original, peer-reviewed papers, with those studies cited more than 46,000 times overall. Connecticut’s highest scientific honour is the Academy of Science’s highest honour, the H-index of 102, conferred upon Dr. Risch.
He has been an outspoken advocate for the use of hydroxychloroquine to treat COVID-19, despite a lack of scientific evidence that it works.
For patients with high-risk COVID-19 infection, Risch stated in an opinion piece in Newsweek on July 23 that hydroxychloroquine and azithromycin, an antibiotic, should be used immediately without waiting for more efficacy studies.
His May 27 publication in the American Journal of Epidemiology was heavily attacked for lacking randomised trials, so he wrote this post.
While this combination of medications is safe for short-term use early in the course of illness, both studies concluded that it can successfully prevent hospitalisation in most symptomatic high-risk outpatients. This assertion has since been widely refuted.
Other disorders, such as rheumatoid arthritis and malaria, were treated with hydroxychloroquine before the COVID-19 pandemic. Hydroxychloroquine has been shown to block SARS-CoV-2 replication in cells by Albert Ko, Department Chair and Professor of Epidemiology at Yale School of Public Health’s early in vitro investigations.
Hydroxychloroquine was backed by President Trump in April. To treat COVID-19, the FDA gave the medicine an Emergency Use Authorization, and WHO and NIH began clinical trials to evaluate its effectiveness.
Despite the fact that both organisations ceased their investigations in the early part of July, the FDA has revoked the treatment’s Emergency Use Authorization due to concerns about its efficacy and safety
There has been a shift in the scientific community’s focus away from hydroxychloroquine due to fresh evidence of its ineffectiveness non treating COVID-19. Some of his colleagues at Yale and beyond have objected to Risch’s differing opinions on the matter.
Members of Yale’s scientific and medical communities expressed their displeasure with Risch’s unwavering support for hydroxychloroquine in a statement published on Medium on August 4. More than 20 Yale faculty members have signed it.
His Ph.D. from the University of Chicago was earned in the same year. He is a researcher who focuses on cancer causation, prevention, early detection, and epidemiologic approaches.
More of a focus for Dr. Harvey is on the influence of reproductive, nutrition, genetic predisposition and histopathological factors on health outcomes. Besides that, he works as an associate editor for the Journal of the National Cancer Institute and an editor for the International Journal of Cancer..
Medical journals have included some of the Professor’s research findings. The Ruth Leff Siegel Award for Excellence in Pancreatic Cancer Research was given to him in 2018 as well.
As a last point of reference, we point to the recent FDA document withdrawing HCQ’s Emergency Use Authorization, which has gathered all of the data on the medicine as of June 2020.
Food and Drug Administration Memorandum Explaining Basis for Revocation of Emergency Use Authorization for Emergency Use of Chloroquine Phosphate and Hydroxychloroquine Sulfate.
For the time being, the Infectious Diseases Society of America recommends against the medication in conjunction with azithromycin for COVID-19. We may change our minds on the use of HCQ in the treatment of COVID-19 if the results of these trials show that it has a therapeutic benefit.
At the start of the pandemic, clinicians at YNHH prescribed hydroxychloroquine and the antibiotic azithromycin to COVID-19 patients, according to Naftali Kaminski, Chief of Pulmonary, Critical Care and Sleep Medicine at the School of Medicine.
Historical evidence suggested that this medicine would work, and given the limited knowledge of the virus at the time, Kaminski believes it was considered a plausible therapeutic choice.
As a result, it is no longer a component of the standard treatment plan. There are no doctors at Yale who are still prescribing it, according to Ko.
The May 27 report, in which Risch was the only author, was consistent with many of the early assumptions about the drug combination.
There is no randomization in any of the five studies Risch provides as evidence for his assertions, and three of the studies are also quite tiny including Gautret et al. 2020, Million et al. 2020, Zelenko 2020, Esper et al. 2020.
His research acknowledges this, but he rationalises that a benefit this big cannot be disproved by lack of randomization. The sample size issue is only relevant when statistical significance is not found, according to him.